TokenPost·
FDA Approves New Roche Drug Uses for Cancer, Kidney and Eye Diseases
The Oct. 8 Tecentriq decision covers a chemotherapy combination for certain stage III colon cancers; Enspryng was cleared for adults with thyroid eye disease on Oct. 15.
More news
- TokenPostMSC Industrial Shifts to Modular AI Strategy, Ends Digital Core Program
- TokenPostS&T Bancorp Expects Margin Above 4%, Targets About 3% 2027 Noninterest Expense Growth
- TokenPostElement Solutions Sets 2026 Adjusted EBITDA Guidance at About $720 Million
- TokenPostNvidia Shares Fall 4.4% as Semiconductor Index Drops 6.8%
- TokenPostBMW Sets U.S. Launch Dates for 2027 X5 Hybrid and Electric Models
- TokenPostBifrost (BFC) Falls 10.48% in an Hour While Up 26.08% in 24 Hours